Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Protagonist Therapeutics, Inc.
  6. News
  7. Summary
    PTGX   US74366E1029

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-06-28 pm EDT
8.450 USD   -7.35%
06/24PROTAGONIST THERAPEUTICS, INC.(NASDAQGM : PTGX) dropped from Russell 2500 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDAQGM : PTGX) dropped from Russell 3000 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDAQGM : PTGX) added to Russell Microcap Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating

05/18/2022 | 06:53am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about PROTAGONIST THERAPEUTICS, INC.
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 2500 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 3000 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell Microcap Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell Small Cap Comp Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 2000 Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell Small Cap Comp Growth In..
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 2000 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 3000 Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 3000E Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 3000E Growth Index
CI
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 31,9 M - -
Net income 2022 -157 M - -
Net cash 2022 174 M - -
P/E ratio 2022 -2,67x
Yield 2022 -
Capitalization 411 M 411 M -
EV / Sales 2022 7,43x
EV / Sales 2023 29,8x
Nbr of Employees 122
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 8,45 $
Average target price 40,00 $
Spread / Average Target 373%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Research & Development Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-75.29%411
MODERNA, INC.-44.02%57 385
IQVIA HOLDINGS INC.-24.79%40 468
LONZA GROUP AG-32.64%39 851
SEAGEN INC.15.44%33 010
CELLTRION, INC.-11.87%18 371